Since TNF- α exerts its effects primarily via modulating the NF-κB pathway, selective inhibitors of the NF-κB pathway, e.g., Bortezomib, have been tested in prostate cancer, myeloma, and ovarian cancer (Richardson et al., 2003; Bruning et al., 2009) (Figure 1). Here, NFKB1 is linked to prostate cancer.